Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRLS - Chrysalis : Any followers ? Any comments ? -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (27)	11/8/1997 6:31:00 PM
From: BulbaMan	Respond to of 51

My feeling is, based on their backlog, CRLS will begin making money soon. And, by my calculations, they had a positive cash flow last quarter (with depreciation and amortization of $708,000), although the EPS was a loss of a penny (-$93,000). They had about $7.8 million in cash on 9/30/97, but CRLS is not a biotech that's burning cash but a going concern -- so, their cash position is pretty decent. The future patent royalties are the big unknown -- but I think the stock is undervalued based just on CRLS's contract research business. You might want to check out their SEC filings for more info.

To: Sleepman who wrote (27)	11/10/1997 1:13:00 PM
From: BulbaMan	Read Replies (1) \| Respond to of 51

I found two Wall Street Journal articles on the cloning of Dolly that mention Chrysalis. Both articles quote Paul Schmitt, Chrysalis CEO, with the WSJ describing Chrysalis as: "The drug-research company (that) holds a patent on the 'microinjection' technique that is commonly used in animal genetic engineering." In addition, Schmitt noted that Chrysalis had licensing arrangements for its DNA microinjection technology with 30 different companies, including PPL (Dolly's daddies).